A New First-Line Standard for EGFR-Mutated NSCLC?

Among patients with non–small-cell lung cancer (NSCLC) and sensitizing mutations in the epidermal growth factor receptor (EGFR) gene, the primacy of first-line osimertinib monotherapy has been challenged by two combination regimens. The MARIPOSA trial showed progression-free survival (PFS) and overall-survival (OS) benefits of amivantamab–lazertinib over osimertinib alone. The phase 3, open-label FLAURA2 trial previously showed a PFS benefit of platinum-pemetrexed chemotherapy with osimertinib over osimertinib alone; the current update reports OS results, a key secondary end point. Investigators randomized 557 patients with locally advanced or metastatic NSCLC and sensitizing EGFR mutations to first-line treatment with osimertinib pl…